The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hereditary Angioedema Therapeutic Market Research Report 2024
Synopsis
Hereditary Angioedema Therapeutic is the treatment for Hereditary Angioedema. Growing cases of hereditary angioedema (HAE) globally is a key market driver.
The global Hereditary Angioedema Therapeutic market was valued at US$ 2088.6 million in 2023 and is anticipated to reach US$ 3050 million by 2030, witnessing a CAGR of 5.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hereditary Angioedema Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Angioedema Therapeutic.
Report Scope
The Hereditary Angioedema Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Angioedema Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Angioedema Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BioCryst Pharma
Ionis Pharma
Pharming Group
CSL Limited
Shire
Attune Pharma
Adverum Biotechnologies
KalVista Pharma
Segment by Type
Intravenous
Subcutaneous
Oral
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Angioedema Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Hereditary Angioedema Therapeutic is the treatment for Hereditary Angioedema. Growing cases of hereditary angioedema (HAE) globally is a key market driver.
The global Hereditary Angioedema Therapeutic market was valued at US$ 2088.6 million in 2023 and is anticipated to reach US$ 3050 million by 2030, witnessing a CAGR of 5.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hereditary Angioedema Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hereditary Angioedema Therapeutic.
Report Scope
The Hereditary Angioedema Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hereditary Angioedema Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hereditary Angioedema Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BioCryst Pharma
Ionis Pharma
Pharming Group
CSL Limited
Shire
Attune Pharma
Adverum Biotechnologies
KalVista Pharma
Segment by Type
Intravenous
Subcutaneous
Oral
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hereditary Angioedema Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hereditary Angioedema Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Intravenous
1.2.3 Subcutaneous
1.2.4 Oral
1.3 Market by Application
1.3.1 Global Hereditary Angioedema Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hereditary Angioedema Therapeutic Market Perspective (2019-2030)
2.2 Hereditary Angioedema Therapeutic Growth Trends by Region
2.2.1 Global Hereditary Angioedema Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hereditary Angioedema Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Hereditary Angioedema Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Hereditary Angioedema Therapeutic Market Dynamics
2.3.1 Hereditary Angioedema Therapeutic Industry Trends
2.3.2 Hereditary Angioedema Therapeutic Market Drivers
2.3.3 Hereditary Angioedema Therapeutic Market Challenges
2.3.4 Hereditary Angioedema Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hereditary Angioedema Therapeutic Players by Revenue
3.1.1 Global Top Hereditary Angioedema Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Hereditary Angioedema Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Hereditary Angioedema Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hereditary Angioedema Therapeutic Revenue
3.4 Global Hereditary Angioedema Therapeutic Market Concentration Ratio
3.4.1 Global Hereditary Angioedema Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hereditary Angioedema Therapeutic Revenue in 2023
3.5 Hereditary Angioedema Therapeutic Key Players Head office and Area Served
3.6 Key Players Hereditary Angioedema Therapeutic Product Solution and Service
3.7 Date of Enter into Hereditary Angioedema Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hereditary Angioedema Therapeutic Breakdown Data by Type
4.1 Global Hereditary Angioedema Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Hereditary Angioedema Therapeutic Forecasted Market Size by Type (2025-2030)
5 Hereditary Angioedema Therapeutic Breakdown Data by Application
5.1 Global Hereditary Angioedema Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Hereditary Angioedema Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hereditary Angioedema Therapeutic Market Size (2019-2030)
6.2 North America Hereditary Angioedema Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hereditary Angioedema Therapeutic Market Size by Country (2019-2024)
6.4 North America Hereditary Angioedema Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hereditary Angioedema Therapeutic Market Size (2019-2030)
7.2 Europe Hereditary Angioedema Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hereditary Angioedema Therapeutic Market Size by Country (2019-2024)
7.4 Europe Hereditary Angioedema Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hereditary Angioedema Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Hereditary Angioedema Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hereditary Angioedema Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Hereditary Angioedema Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hereditary Angioedema Therapeutic Market Size (2019-2030)
9.2 Latin America Hereditary Angioedema Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hereditary Angioedema Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Hereditary Angioedema Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hereditary Angioedema Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Hereditary Angioedema Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hereditary Angioedema Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Hereditary Angioedema Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioCryst Pharma
11.1.1 BioCryst Pharma Company Detail
11.1.2 BioCryst Pharma Business Overview
11.1.3 BioCryst Pharma Hereditary Angioedema Therapeutic Introduction
11.1.4 BioCryst Pharma Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.1.5 BioCryst Pharma Recent Development
11.2 Ionis Pharma
11.2.1 Ionis Pharma Company Detail
11.2.2 Ionis Pharma Business Overview
11.2.3 Ionis Pharma Hereditary Angioedema Therapeutic Introduction
11.2.4 Ionis Pharma Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.2.5 Ionis Pharma Recent Development
11.3 Pharming Group
11.3.1 Pharming Group Company Detail
11.3.2 Pharming Group Business Overview
11.3.3 Pharming Group Hereditary Angioedema Therapeutic Introduction
11.3.4 Pharming Group Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.3.5 Pharming Group Recent Development
11.4 CSL Limited
11.4.1 CSL Limited Company Detail
11.4.2 CSL Limited Business Overview
11.4.3 CSL Limited Hereditary Angioedema Therapeutic Introduction
11.4.4 CSL Limited Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.4.5 CSL Limited Recent Development
11.5 Shire
11.5.1 Shire Company Detail
11.5.2 Shire Business Overview
11.5.3 Shire Hereditary Angioedema Therapeutic Introduction
11.5.4 Shire Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.5.5 Shire Recent Development
11.6 Attune Pharma
11.6.1 Attune Pharma Company Detail
11.6.2 Attune Pharma Business Overview
11.6.3 Attune Pharma Hereditary Angioedema Therapeutic Introduction
11.6.4 Attune Pharma Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.6.5 Attune Pharma Recent Development
11.7 Adverum Biotechnologies
11.7.1 Adverum Biotechnologies Company Detail
11.7.2 Adverum Biotechnologies Business Overview
11.7.3 Adverum Biotechnologies Hereditary Angioedema Therapeutic Introduction
11.7.4 Adverum Biotechnologies Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.7.5 Adverum Biotechnologies Recent Development
11.8 KalVista Pharma
11.8.1 KalVista Pharma Company Detail
11.8.2 KalVista Pharma Business Overview
11.8.3 KalVista Pharma Hereditary Angioedema Therapeutic Introduction
11.8.4 KalVista Pharma Revenue in Hereditary Angioedema Therapeutic Business (2019-2024)
11.8.5 KalVista Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
